| GLAUKOS CORP. DL-,001 |
| USA |
| Gesundheit |
| US3773221029 / A14VCK |
| 6GJ (Frankfurt) / GKOS (NYSE) |
| FRA:6GJ, ETR:6GJ, 6GJ:GR, NYSE:GKOS |
| - |
| https://www.glaukos.com/ |
|
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surge..
>Volltext.. |
| 9580.18 Mio. EUR |
| 9419.99 Mio. EUR |
| 549.41 Mio. EUR |
| -29.18 Mio. EUR |
| -168.59 Mio. EUR |
| -2.92 EUR |
| 92.19 Mio. EUR |
| 102.64 Mio. EUR |
| -0.85 Mio. EUR |
| 2.8 |
| 46% |
| -109.03% |
| - |
| - |
| - |
| GLAUKOS |
| 28.10.26 |
|